🔎 Trials Near Me

Home › Neuroblastoma › Massachusetts › Boston

Neuroblastoma clinical trials in Boston, MA

13 studies for Neuroblastoma are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

RecruitingPhase 3
  • Massachusetts General Hospital Cancer Center, Boston
  • Dana-Farber Cancer Institute, Boston
Up to age 30 · All sexes · Updated Sep 24, 2026 · NCT06172296

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

RecruitingPhase 1/2
  • Dana-Farber Cancer Institute ( Site 1013), Boston
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103

B7-H3.CD28Z.CART in Solid Tumors

RecruitingPhase 1
  • Dana Farber Cancer Institite, Boston
9 Months – 30 Years · All sexes · Updated Sep 3, 2026 · NCT07358260

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

RecruitingPhase 1/2
  • Dana-Farber Cancer Institute, Boston
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

RecruitingPhase 3
  • Massachusetts General Hospital Cancer Center, Boston
  • Dana-Farber Cancer Institute, Boston
365 Days – 30 Years · All sexes · Updated Aug 25, 2026 · NCT03126916

SPEARHEAD-3 Pediatric Study

RecruitingPhase 1/2
  • Dana Farber Cancer Institute, Boston
Ages 2 to 21 · All sexes · Updated Aug 11, 2026 · NCT05642455

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

RecruitingPhase 1/2
  • Boston Children's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 1 to 30 · All sexes · Updated Jul 22, 2026 · NCT06721689

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

RecruitingPhase 2
  • Boston Children's Hospital, Dana-Farber Cancer Institute., Boston
Ages 1 to 31 · All sexes · Updated Jul 20, 2026 · NCT06450041

Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

RecruitingPhase 1
  • Boston Children's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Ages 1 to 30 · All sexes · Updated Jul 14, 2026 · NCT07027748

Neuroblastoma Biology Study

RecruitingObservational study
  • Children's Hospital Boston, Boston
31 Days – 99 Years · All sexes · Updated Mar 23, 2026 · NCT01587300

Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma

Recruiting
  • Dana-Farber Cancer Institute, Boston
Up to age 17 · All sexes · Updated Feb 10, 2026 · NCT06831552

Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma

RecruitingPhase 1/2
  • Boston Children's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
12 Months – 29 Years · All sexes · Updated Dec 26, 2025 · NCT06803875

MCT for the Harvard/UCSF ROBIN Center

Recruiting
  • Brigham and Women's Hospital, Boston
All ages · All sexes · Updated Feb 17, 2025 · NCT06000787

About Neuroblastoma

Neuroblastoma is a cancer in nerve tissue in the adrenal gland, neck, chest, or spinal cord. It often affects young children. Read about treatments.

More about Neuroblastoma on MedlinePlus

Neuroblastoma trials in other cities

Other studies in Boston

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.